Table 2 Summary of the results of prior studies in patients with anti-GBM disease between 2000 and 2020
Reference | Country | Study period (year) | Sample size (n) | Age (years) | sCr (mg/dl) | Anti-GBM measurement method | eGFR (ml/min/1.73 m2) | Lung involvement(%) | Prednisolone (%) | Cyclophosphamide (%) | Plasmapheresis (%) | Infectious complication (%) | Relapse rate (%) | 1-year survival (%) | 5-year survival (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Levy et al. [7] | UK | 1975–1999 | 81 | 40 | 3.6 | ELISA | NA | 62 | 100 | 100 | 100 | NA | 3 | 79 | NA |
Segelmark et al. [3] | Sweden | 1987–1995 | 79 | 59 | NA | ELISA | NA | 21 | NA | NA | NA | NA | NA | 66* | NA |
Li et al. [8] | China | 1992–2003 | 10 | 59 | NA | ELISA or IIF | NA | 80 | 80 | 80 | 80 | 0 | 0 | 80 | NA |
Rutgers et al. [9] | Netherlands | 1978–2003 | 24 | 57 | 9.9 | ELISA | NA | NA | 54 | 54 | 54 | NA | NA | 91 | NA |
Hirayama et al. [5] | Japan | 1989–2000 | 47 | 51 | 7.5 | NA | NA | 23 | 85 | 36 | 55 | NA | 14 | 67* | NA |
Kitagawa et al. [4] | Japan | 1995–2005 | 16 | 61 | 8.2 | NA | NA | 25 | NA | NA | NA | NA | NA | 88 | NA |
Cui et al. [2] | China | 1998–2008 | 221 | 39 | 9.5 | ELISA | NA | 46 | 80 | 34 | 76 | NA | NA | 73 | NA |
Dammacco et al. [10] | Italy | 2003–2012 | 10 | 49 | NA | ELISA | NA | 60 | 100 | 100 | 100 | NA | 20 | 80 | NA |
Alchi et al. [11] | UK | 1991–2011 | 43 | 53 | NA | Radioimmunoassay | NA | 40 | 74 | 74 | 74 | NA | 0 | 88 | NA |
Huart et al. [12] | France | 1983–2006 | 122 | 31 | 7.2 | ELISA | NA | 91 | 97 | 84 | 100 | NA | NA | 87 | NA |
Canney et al. [13] | Ireland | 2003–2014 | 79 | 63 | NA | ELISA | NA | 98 | NA | NA | NA | NA | NA | 62 | 24 |
McAddo et al. [14] | Czech, UK, and Sweden | 2000–2013 | 78 | 61 | 3.3 | ELISA or IIF | 20§ | 38 | 100 | 92 | 89 | NA | 0 | 86 | NA |
Marques et al. [15] | France | 1981–2017 | 119 | 54 | 7.2 | ELISA | NA | 45 | 97 | 82 | 82 | 2 | 3 | 95 | 92 |
Caillard et al. [16] | France | 1997–2017 | 201 | 53 | 7.4 | IIF and/or antigen-specific immunoassay | NA | 37 | 97 | 81 | 77 | 58 | NA | 92 | 79 |
Our case series | Japan | 2000–2020 | 12 | 70 | 8.5 | ELISA | 5 | 42 | 100 | 0 | 67 | 3 | 8 | 82 | 68 |